GHRS vs CYBN vs CMPS vs MNMD

Analysts rate GH Research PLC (GHRS) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison.

The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, GH Research PLC (GHRS) delivered a total return of +9.

1%, compared to -90. 3% for Cybin Inc. (CYBN). Over 10 years, the gap is even starker: MNMD returned +512. 1% versus CYBN's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), COMPASS Pathways plc (CMPS) is the lower-risk stock at 1.

33β versus GH Research PLC's 1. 72β — meaning GHRS is approximately 29% more volatile than CMPS relative to the S&P 500.

On earnings-per-share growth, the picture is similar: Cybin Inc.

grew EPS 93. 5% year-over-year, compared to -1273. 3% for Mind Medicine (MindMed) Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

GH Research PLC (GHRS) is the more profitable company, earning 0.

0% net margin versus 0. 0% for Mind Medicine (MindMed) Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GHRS leads at 0. 0% versus 0. 0% for MNMD. At the gross margin level — before operating expenses — GHRS leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Mind Medicine (MindMed) Inc.

(MNMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+512. 1% 10Y return). GH Research PLC (GHRS) carries a higher beta of 1. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MNMD: +512. 1%, GHRS: +9. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.